Vertex Pharmaceuticals Inc., adjusted total assets

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Total assets	22,533,200)	22,730,200)	18,150,900)	13,432,500)	11,751,808)
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Less: Deferred tax assets²	2,331,100)	1,812,100)	1,246,900)	934,500)	882,779)
After Adjustment
Adjusted total assets	20,202,100)	20,918,100)	16,904,000)	12,498,000)	10,869,029)

¹ Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

² Deferred tax assets. See details »

Download chart

Vertex Pharmaceuticals Inc., adjusted shareholders’ equity

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Shareholders’ equity	16,409,600)	17,580,400)	13,912,700)	10,100,000)	8,686,815)
Adjustments
Less: Net deferred tax assets (liabilities)¹	2,331,100)	1,812,100)	1,246,900)	934,500)	882,779)
After Adjustment
Adjusted shareholders’ equity	14,078,500)	15,768,300)	12,665,800)	9,165,500)	7,804,036)

¹ Net deferred tax assets (liabilities). See details »

Download chart

Vertex Pharmaceuticals Inc., adjusted capitalization table

US$ in thousands

	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Current finance lease liabilities	5,200)	50,600)	40,800)	46,900)	42,434)
Long-term finance lease liabilities	112,800)	376,100)	430,800)	509,800)	539,042)
Total reported debt	118,000)	426,700)	471,600)	556,700)	581,476)
Shareholders’ equity	16,409,600)	17,580,400)	13,912,700)	10,100,000)	8,686,815)
Total reported capital	16,527,600)	18,007,100)	14,384,300)	10,656,700)	9,268,291)
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)¹	—)	—)	—)	—)	—)
Add: Current operating lease liabilities²	87,100)	33,100)	48,600)	33,300)	10,521)
Add: Long-term operating lease liabilities³	1,544,400)	348,600)	379,500)	377,400)	350,463)
Adjusted total debt	1,749,500)	808,400)	899,700)	967,400)	942,460)
Adjustments to Equity
Less: Net deferred tax assets (liabilities)⁴	2,331,100)	1,812,100)	1,246,900)	934,500)	882,779)
Adjusted shareholders’ equity	14,078,500)	15,768,300)	12,665,800)	9,165,500)	7,804,036)
After Adjustment
Adjusted total capital	15,828,000)	16,576,700)	13,565,500)	10,132,900)	8,746,496)

¹ Operating lease liability (before adoption of FASB Topic 842). See details »

² Current operating lease liabilities. See details »

³ Long-term operating lease liabilities. See details »

⁴ Net deferred tax assets (liabilities). See details »

Download chart

Vertex Pharmaceuticals Inc., adjusted net income (loss)

US$ in thousands

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
As Reported
Net income (loss)	(535,600)	3,619,600)	3,322,000)	2,342,100)	2,711,647)
Adjustments
Add: Deferred income tax expense (benefit)¹	(348,800)	(536,500)	(275,900)	(154,600)	277,341)
Add: Other comprehensive income (loss)	142,100)	(15,100)	(15,100)	84,400)	(66,507)
After Adjustment
Adjusted net income (loss)	(742,300)	3,068,000)	3,031,000)	2,271,900)	2,922,481)

¹ Deferred income tax expense (benefit). See details »

Download chart

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Adjustments to Financial Statements